Daratumumab for the Treatment of Patients With AL Amyloidosis
Status:
Completed
Trial end date:
2020-07-17
Target enrollment:
Participant gender:
Summary
Participants with AL Amyloidosis will receive the drug daratumumab by IV infusion once weekly
for two months, then every 2 weeks for four months, then once each month. Study treatment may
continue until disease progression, unacceptable toxicity, or decision to withdraw from the
trial. Disease evaluations will be performed every three months until disease progression.